Provider: View Press Release
Type: Link
Title: GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC) | GSK
Description: EAGLE-1 trial met its primary efficacy endpoint.
Provider: View Press Release
Type: Link
Title: LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges | GSK
Description: Full data set to be presented at an upcoming scientific conference.
Provider: View Press Release
Type: Link
Title: GSK completes acquisition of Aiolos Bio | GSK
Description: GSK has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company.
Provider: View Press Release
Type: Link
Title: GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B | GSK
Description: Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)
Provider: View Press Release
Type: Link
Title: GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk | GSK
Description: GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.
Provider: View Press Release
Type: Link
Title: GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration | GSK
Description: Shingrix already approved in China for adults aged 50 years and over.